Understanding how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it hopes to find new ways to help patients with this type of cancer live longer and healthier lives.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10977511 on NIH RePORTER |
What this research studies
This research investigates the role of Angiopoietin-2 (Ang2) in the development of liver metastasis in patients with pancreatic neuroendocrine tumors (PanNET). By examining how Ang2 interacts with the Tie2 receptor, the study aims to uncover mechanisms that contribute to tumor growth and immune evasion. The researchers will utilize a mouse model to explore the effects of inhibiting Ang2 on liver metastasis and overall survival. This approach could lead to new therapeutic strategies for patients suffering from metastatic PanNET.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic neuroendocrine tumors, particularly those with liver metastasis.
Not a fit: Patients with non-pancreatic tumors or those without liver metastasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with metastatic pancreatic neuroendocrine tumors.
How similar studies have performed: Preliminary studies have shown success in using Ang2 inhibition to suppress liver metastatic growth in a mouse model, indicating potential for similar approaches in humans.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Kim, Minah — Columbia University Health Sciences
- Study coordinator: Kim, Minah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.